EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prognostic analysis of HALP -LDH composite model in newly diagnosed diffuse large B-cell lymphoma patients

Yugang Yan, Kewen Li, Qinhua Yu, Liannv Qiu

Frontiers in Physiology · 30.10.2026 · 17

DOI: 10.3389/fphys.2026.1877689 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Physiology, online erschienen am 30.10.2026. Verfasst von Yugang Yan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Quzhou Hospital of Traditional Chinese Medicine, Quzhou, Zhejiang, China. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The hemoglobin–albumin–lymphocyte–platelet (HALP) score is a prognostic marker in several types of malignant tumors. The prognostic value of HALP -Lactate dehydrogenase (LDH) composite model in diffuse large B-cell lymphoma (DLBCL) remains unknown.

Objective

We aim to determine the prognostic value of the HALP +LDH composite model in DLBCL patients.

Methods

We retrospectively analyzed their clinical data and laboratory parameters from 112 newly diagnosed DLBCL patients treated with R-CHOP regimens at Zhejiang Provincial People’s Hospital from January 2014 to October 2021. According to HALP score, these patients were divided into a high-HALP group (HALP score>24.92, n=65) and a low-HALP group (HALP score ≤ 24.92, n=47). We evaluated the significance of baseline HALP +LDH composite model as a predictor of response to treatment, overall survival (OS), progression-free survival (PFS) and clinicopathological characteristics. The risk score formula was generated based on the regression coefficients of model.

Results

The median follow-up duration for the entire cohort was 36 months. DLBCL patients with a low HALP score (≤24.92) exhibit significantly adverse clinical and biological features, including advanced Ann Arbor stage (III–IV), elevated International Prognostic Index (IPI) score (3–5), LDH ≥250U/L, and ≥2 extranodal sites of involvement (all P < 0.05). A low HALP score (≤24.92) effectively identifies high-risk DLBCL patients and serves as an independent predictor of poor OS and PFS beyond other clinical characteristic, IPI. Additional independent predictors identified in the Cox regression analysis included advanced Ann Arbor stage III–IV, poor performance status (ECOG score ≥2), IPI score 3–5, LDH ≥250U/L and HALP (≤24.92). Furthermore, two combined models (HALP + LDH and HALP + IPI) significantly improves the assessment of patient prognosis (AUC = 0.717), superior to the individual predictive value of HALP score, LDH, or IPI alone.

Conclusion

The HALP+LDH composite model enhances prognostic accuracy in DLBCL and complements conventional scoring systems.

Schlagwörter

Stichwörter der Autor:innen

HALP scorediffuse large B cell lymphomalactate dehydrogenaseprognosissurvival

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Quzhou Hospital of Traditional Chinese Medicine, Quzhou, Zhejiang, China.
  • Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China.
  • School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.

Zitieren

APA

Yan, Y., Li, K., Yu, Q., & Qiu, L. (2026). Prognostic analysis of HALP -LDH composite model in newly diagnosed diffuse large B-cell lymphoma patients. Frontiers in Physiology, 17. https://doi.org/10.3389/fphys.2026.1877689

Vancouver

Yan Y, Li K, Yu Q, Qiu L. Prognostic analysis of HALP -LDH composite model in newly diagnosed diffuse large B-cell lymphoma patients. Frontiers in Physiology. 2026;17. doi:10.3389/fphys.2026.1877689

BibTeX
@article{Yan2026,
  author = {Yan, Yugang and Li, Kewen and Yu, Qinhua and Qiu, Liannv},
  title = {Prognostic analysis of HALP -LDH composite model in newly diagnosed diffuse large B-cell lymphoma patients},
  journal = {Frontiers in Physiology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphys.2026.1877689}
}
Kostenlos starten →